ScholarWorks@SUNGKYUNKWAN UNIVERSITY: CHUNG, JAE HOON

Detailed Information

CHUNG, JAE HOON (정재훈)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Thyroid cancer:12||papillary thyroid carcinoma:11||Prognosis:11||thyroid cancer:9||Mortality:8||BRAF:8||Thyroid neoplasms:8||Iodine:8||Korea:7||Thyroid hormones:6||thyroid neoplasm:6||TNM staging:6||Ultrasonography:5||Antithyroid agents:5||Recurrence:5||prognosis:5||Biopsy:5||Differentiated thyroid cancer:5||thyroid:5||Republic of Korea:4||calcitonin:4||fineneedle aspiration:4||TERT promoter:4||Thyrotropin:4||Prostate cancer:4||Graves disease:4||recurrence:4||Pregnancy:4||Graves&apos:3||age:3||Radioactive iodine:3||갑상선암:3||survival:3||Hypothyroidism:3||hypothyroidism:3||Diagnosis:3||renal cell carcinoma:3||Prostatic neoplasms:3||immunotherapy:3||Renal cell carcinoma:3||mortality:3||Lymph nodes:3||Medullary thyroid carcinoma:3||Papillary thyroid carcinoma:3||active surveillance:3||Hyperthyroidism:3||differentiated thyroid carcinoma:3||Mutation:3||disease:3||BRAF mutation:3||thyroid nodule:3||Metabolic syndrome:3||초음파:2||Guideline:2||prostate cancer:2||Radioactive iodine therapy:2||prostatespecific antigen:2||Fineneedle aspiration:2||TSH suppression:2||Radiotherapy:2||Follicular thyroid carcinoma:2||radioactive iodine therapy:2||Incidence:2||Receptors:2||remission:2||Thyroid:2||Reference intervals:2||risk:2||anaplastic carcinoma:2||kidney:2||Iodine radioisotopes:2||sorafenib:2||Prevalence:2||biopsy:2||lymph node metastasis:2||lymph nodes:2||bladder cancer:2||thyroglobulin:2||medullary thyroid carcinoma:2||metastasis:2||childhood:2||PET:2||Papillary:2||Thyroidectomy:2||multifocality:2||Prostate:2||nephroureterectomy:2||diabetes:2||diagnosis:2||ultrasonography:2||overall survival:2||differentiated thyroid cancer:2||papillary thyroid cancer:2||papillary thyroid microcarcinoma:2||Treatment outcome:2||Triiodothyronine:2||Prostatectomy:2||Neoplasm metastasis:2||IMDC poorrisk:1||Immunochemiluminometric assay:1||Immunoglobulins:1||Inherited thyroxinebinding globulin deficiency:1||Iodinesufficient area:1||Iodothyronine deiodinase:1||Kidney failure:1||Korean Thyroid Association:1||Koreans:1||Learning curve:1||Leonard D Kohn:1||Lowiodine diet:1||Lymph node ratio:1||Lymphocyte:1||MALT lymphoma:1||Macroadenoma:1||Magnetic resonance imaging:1||Metabolically healthy obese:1||Metanephrine:1||Metastasis:1||Microadenoma:1||Miles’ operation:1||Monoclonal antibody:1||Mutat:1||Mutation rate:1||NIFTP:1||NTproBNP:1||Nationwide study:1||Neoplasm invasiveness:1||Neoplasm staging:1||Neutrophil:1||Neutrophiltolymphocyte ratio:1||Nocturia:1||Nomogram:1||Nonimmunerelated hypothyroidism:1||Nondiagnostic:1||Obesity:1||Oncologic outcome:1||Osteoporosis:1||Outcome Assessment (Health Care):1||PD1:1||PDL1:1||PET/CT:1||Papillary cancer:1||Papillary thyroid cancer:1||Parathyroid adenoma:1||Parathyroid carcinoma:1||Parathyroid hormone:1||Parathyroid hyperplasia:1||Parathyroid scintigraphy:1||Parkinson's disease:1||Pathologic features:1||Pediatric:1||Performance:1||Pheochromocytoma:1||Phosphodiesterase 5 inhibitors:1||Pituitary ACTH Hypersecretion:1||Pituitary Adenoma:1||Plasma surface modification:1||Polymerase chain reactionsequence based typing:1||Polymorphism:1||Prediction:1||Predictive factors:1||Primary hyperparathyroidism:1||Primary lymphoma of thyroid:1||Prognosticator:1||Programmed Cell Death 1:1||Programmed cell death 1 ligand 1:1||Prospective registry:1||Prostate Cancer:1||Prostate Imaging Reporting and Data System (PIRADS):1||Prostate biopsy:1||ProstateSpecific Antigen:1||Prostatespecific antigen:1||Prostatic Neoplasms:1||Prostatic neoplasm:1||Prostatic secretory proteins:1||Psychological wellbeing:1||RAS:1||RAS mutations:1||Radical nephrectomy:1||Radioiodine:1||Randomized control trial:1||Rate of change in thyroidstimulating hormone:1||Recombinant human thyrotropin:1||Recursive partitioning analysis:1||Rehabilitation:1||Reliability:1||Renal compensation:1||Renal function:1||Renal metastasis:1||Reporting and data system (TIRADS):1||Reporting quality:1||Retropubic:1||Risk:1||Risk factors:1||Robotic:1||SERPINA7 protein, human:1||SOFA Score:1||Sarcopenia:1||Screening:1||Screening interval:1||Selenium:1||Selfmonitoring of blood glucose:1||Serum selenium:1||Shear wave elastography:1||Sitagliptin:1||Sleep:1||Sonography:1||South Korea:1||Stents:1||Survival:1||Systematic biopsy:1||TAZ:1||TERT:1||TERT promoter mutation:1||TSH:1||TT cells:1||Tall cell variant:1||Targeted biopsy:1||Tc99m Sestamibi:1||Telomerase reverse transcriptase:1||Telomerase reverse transcriptase promoter mutation:1||Thyroglobulin:1||Thyroid Hormone Receptor:1||Thyroid Hormone Receptors beta:1||Thyroid Hormone Resistance Syndrom:1||Thyroid Neoplasms:1||Thyroid function:1||Thyroid gland:1||Thyroid hormone withdrawal:1||Thyroid imaging:1||Thyroid lymphoma:1||Thyroid neoplasm:1||Thyroid nodule:1||Thyroid nodules:1||Thyroidstimulating:1||Thyroidstimulating hormone:1||Thyrotropin alfa:1||Thyrotropinbinding inhibitory immunoglobulin:1||Thyroxine:1||Thyroxinebinding globulin:1||Thyroxinebinding globulin deficiency:1||Trace elements:1||Transperineal:1||Transperineal US:1||Type 1 diabetes mellitus:1||Type 2:1||Ultrasound:1||Unsatisfactory:1||Ureter:1||Ureteral obstruction:1||Ureteroscopy:1||Urinary calcium excretion:1||Urinary iodine:1||Urinary sodium excretion:1||Urine iodine:1||Urine selenium:1||Validity:1||Variant:1||Varicocele:1||Vasectomy:1||Vitamin D insufficiency:1||YAP1:1||Young?s modulus:1||Zinc:1||adult:1||adverse event:1||amorphous carbon:1||amyloid:1||antithyroid drug (ATD):1||atrial fibrillation:1||autophagy:1||bidirectionality:1||biofouling:1||biomarker:1||biomarkers:1||bladder:1||calculi:1||cancer:1||cardiovascular disease:1||cell cycle:1||cell proliferation:1||chitosan:1||#UroBPH:1||clinical decision making:1||clinical decisionmaking:1||cohort study:1||core needle biopsy:1||cytopathology:1||delayed recovery:1||detection:1||diffuse sclerosing variant:1||dynamic risk stratification:1||dyslipidemia:1||enzalutamide resistance:1||epidemiology:1||extranodal extension:1||fibrosis:1||fineneedle:1||follicular:1||follicular lesion of undetermined significance:1||follicular thyroid carcinoma:1||gelatine:1||gender:1||glomerular filtration rate:1||graves’ disease:1||health screening:1||heterophilic antibody:1||homocysteine:1||hormonal therapy:1||hypercalcitoninemia:1||hypertrophy:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunoradiometric assay:1||impact of therapy:1||incidence:1||incidentaloma:1||increase:1||induced pluripotent stem cells:1||interference:1||interventional ultrasonography:1||iodinereplete area:1||islet amyloid polypeptide:1||islets:1||kidney neoplasms:1||lasers:1||left ventricular dysfunction:1||lenvatinib:1||leukocyte:1||levothyroxine:1||lung metastasis:1||lymph node dissection:1||lymph node excision:1||magnetic resonance imaging:1||matrixassisted laser desorption ionization timeofflight (MALDITOF):1||medullary carcinoma:1||medullary thyroid cancer:1||metabolic:1||metabolic syndrome:1||methylmalonic acid:1||micropapillary variant:1||mitochondrial dynamics:1||modification of tubes:1||molecular diagnostic technique:1||molecular features:1||multiparametric magnetic resonance imaging:1||mutation:1||neoplasm metastasis:1||nephrectomy:1||nonsmall cell lung cancer:1||oligomer:1||osteoporosis:1||oxcarbazepine:1||pain:1||papi:1||papillary carcinoma:1||papillary carcinomas:1||paraganglioma:1||pediatric patients:1||pediatrics:1||pheochromocytoma:1||poloxamer:1||poorly differentiated thyroid carcinoma:1||populationbased study:1||postoperative spindle cell nodule:1||pregnancy:1||prognostic factor:1||programmed death ligand1:1||progression:1||progressionfree survival:1||propensity score:1||prospective study:1||prostate health index:1||prostate imaging and reporting and data system:1||prostate imaging reporting and data system:1||prostatic hyperplasia:1||prostatic neoplasms:1||proteinuria:1||radiation therapy:1||radical cystectomy:1||radioactive iodine:1||radioactive iodine refractory:1||radioactive iodine treatment:1||radioiodine:1||radioiodinerefractory differentiated thyroid carcinoma:1||realworld clinical practice:1||recombinant human TSH:1||recurrence pattern:1||relapse:1||responsiveness:1||retPTC fusion oncoproteins:1||risk factors:1||risk stratification:1||riskstratification system:1||robotic:1||s disease:1||salvage treatment:1||second malignancy:1||selection bias:1||squamous differentiation:1||statistics:1||structural disease:1||success rate:1||sunitinib:1||surgery:1||syndrome:1||the Bethesda system for reporting thyroid cytopathology:1||thyrocyte:1||thyroid autoimmunity:1||thyroid biology:1||thyroid carcinoma:1||thyroid carcinomas:1||thyroid disease:1||thyroid function:1||thyroid neoplas:1||thyrotrophin:1||thyrotropin receptor antibody:1||thyrotropinbinding inhibitory immunoglobulins:1||total thyroidectomy:1||transrectal ultrasound:1||transurethral resection of prostate:1||treatment outcome:1||trend:1||tumor biomarkers:1||tumor growth:1||tumor microenvironment:1||tumor volume:1||tumor volume doubling time:1||ultrasound:1||upper tract urothelial carcinoma:1||upstream stimulatory factor (USF):1||ureteral stent:1||urethral recurrence:1||urethral stricture:1||urinary albumin excretion:1||urothelial carcinoma:1||urothelium cancer:1||vascular invasion:1||vitamin B12:1||young:1||βcatenin:1||갑상선절제술:1||국민조사:1||대한갑상선학회:1||발생률:1||방사성요오드 치료:1||선별 검사:1||유두암:1||진료권고안:1||진료지침:1||chronic:1||(V600E):1||21Hydroxylase Def:1||25hydroxyvitamin D:1||APC gene mutation:1||ARV7:1||Abiraterone acetate:1||Ablation:1||Abnormal thyroid function test:1||Acromegaly:1||Active surveillance:1||Adenocarcinoma:1||Adrenal Insufficiency:1||Agranulocytosis:1||Albumin gene:1||Alzheimer&apos:1||Anaplastic thyroid carcinoma:1||Apnea:1||Apoptosis:1||Atypia of undetermined significance:1||BMD testing:1||BMI:1||BRAF(V600E) mutation:1||BRAFprevalent population:1||BRAFmutation:1||Biochemical markers of bone turnover:1||Biofilms:1||Biological assay:1||Biopsy outcomes:1||Biopsy techniques:1||Body composition:1||Body weight:1||Bone density:1||Bone diseases:1||Bone mineral density:1||Bone resorption marker:1||C11 methionine:1||CHOP:1||CMVPTC:1||CONSORT statement:1||CalciumSensing:1||Cancer screening:1||Cancer survivor:1||Cause of death:1||Cell cycle arrest:1||Certified Reference Material 457 (CRM457):1||Chronic kidney disease:1||Cobalt:1||Combination:1||Complication:1||Congenital Adrenal Hyperplasia:1||Congenital abnormalities:1||Consensus development conference:1||Continuous glucose monitoring:1||Continuous glucose monitoring system:1||Copper:1||Core biopsy:1||Costeffectiveness:1||Critical Illness:1||Database:1||Deletion:1||Dexamethasone:1||Diabetes mellitus:1||Dietary sodium intake:1||Diffuse large B cell lymphoma:1||Distant metastasis:1||Docetaxel:1||Durability:1||DxI 800:1||Dynamic risk stratification:1||Endometriosis:1||Epidemiology:1||Euthyroid:1||Evaluation:1||Excess iodine:1||F18 fluorodeoxyglucose:1||F18FDG:1||FAP:1||FRTL5 cells:1||Familial dysalbuminemic hyperthyroxinemia:1||Fat percentage:1||Fine needle aspiration cytology:1||Gleason score:1||Glucose tolerance test:1||Glycosylated:1||Graves' disease:1||Grave’s disease:1||Growth hormone:1||HLADRB1:1||Hemoglobin A:1||Hormesis:1||Hormones:1||Hypocalcemia:1||Hypoparathyroidism:1||Hypothyroid:1||Hypoxia:1||I131 whole body scan:1||ICPMS:1||

STATISTICS: Total View :5,282,645; Today View :443

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE